BPC-157 and TB-500 are the two most-studied tissue-repair peptides in preclinical literature, and they are almost always used in combination in well-designed recovery studies. The reason is mechanistic complementarity: BPC-157 operates primarily through the nitric oxide (NO/eNOS) and VEGFR2/FAK angiogenic pathway, while TB-500 (Thymosin Beta-4) sequesters G-actin and activates the ILK/Akt/NF-κB pathway to reduce inflammation and mobilize progenitor cells. These pathways do not compete — they address different phases of tissue repair at different times.
This guide covers how to use both compounds in a structured 3-month research protocol: the published dose data that informs practical amounts, how to prepare each vial using bacteriostatic water, timing and injection site rotation, a weekly schedule template, and the biomarkers worth tracking.
Research Use Only. BPC-157 and TB-500 are for in vitro and preclinical in vivo research purposes only. This guide references doses from published rodent studies. Neither compound is approved for human use.
Step 1: Understand the Published Dose Data
Before preparing any solution, understanding what doses appear in published research is critical. Using amounts far outside the published range makes your results non-comparable to the literature.
BPC-157 Published Rodent Doses
Sikiric et al. published the most frequently cited BPC-157 rodent protocols. The standard intraperitoneal (IP) dose range is 10–100 µg/kg body weight, with the 10 µg/kg once-daily dose appearing most consistently across tendon, ligament, and gastrointestinal studies. In a 250 g rat, this corresponds to approximately 2.5 µg absolute. For subcutaneous (SC) administration, some protocols use slightly higher doses (100 µg/kg) to account for variable bioavailability.
TB-500 (Thymosin Beta-4) Published Rodent Doses
Thymosin Beta-4 (Tβ4) studies by Bock-Marquette and colleagues used 150–600 µg/kg SC in mice, typically administered 2–3 times per week rather than daily. The lower end of this range (150 µg/kg) was effective in the cardiac injury models; the 500–600 µg/kg range was used in Ehrlich's wound healing models and musculoskeletal studies. TB-500's longer biological half-life (actin-bound depot) means daily administration is generally not necessary.
| Compound | Standard Dose | Route | Frequency | Reference |
|---|---|---|---|---|
| BPC-157 | 10 µg/kg | IP / SC | Once daily | Sikiric et al. 2003–2018 |
| BPC-157 (high) | 100 µg/kg | SC | Once daily | Sikiric et al. (GI models) |
| TB-500 (low) | 150 µg/kg | SC | 2–3× / week | Bock-Marquette 2004 |
| TB-500 (standard) | 500 µg/kg | SC | 2–3× / week | Ehrlich & Bhatt 2010 |
| TB-500 (high) | 600 µg/kg | SC / IM | 2× / week | Musculoskeletal models |
Step 2: Reconstitute Each Vial
Both BPC-157 and TB-500 are lyophilized (freeze-dried) peptides that require reconstitution with bacteriostatic water (BAC water, 0.9% benzyl alcohol in sterile water for injection) before use. Do not use plain sterile water for multi-dose vials — benzyl alcohol is the antimicrobial preservative that prevents bacterial growth between uses.
Reconstitution Walkthrough (Using the Calculator)
- Navigate to the Nexphoria Reconstitution Calculator at /tools/reconstitution-calculator
- For a 5 mg BPC-157 vial: enter 5 mg vial size, desired concentration of 500 µg/mL → calculator outputs 10 mL BAC water needed
- For a 10 mg TB-500 vial: enter 10 mg vial size, desired concentration of 1,000 µg/mL → calculator outputs 10 mL BAC water needed
- Wipe the rubber stopper of the peptide vial with an alcohol swab and allow to dry
- Inject BAC water slowly against the inner wall of the vial — never shoot directly onto the lyophilized cake
- Gently swirl (never vortex) until the cake dissolves completely — BPC-157 typically dissolves in 30–60 seconds; TB-500 may take 1–2 minutes
- Allow the solution to equilibrate for 2–3 minutes before drawing doses
Volume Tip: For rodent studies, many researchers prefer a 1 mg/mL (1,000 µg/mL) concentration for TB-500 because it minimizes injection volume per dose while keeping the vial multi-use. For BPC-157, 500 µg/mL allows precise dosing at the 10 µg/kg range without requiring sub-µL syringes.
Step 3: Understand the Timing Rationale
The timing difference between BPC-157 and TB-500 is not arbitrary — it reflects their different roles in the repair cascade.
Why Daily vs 2–3×/Week?
BPC-157 appears to have a relatively short plasma half-life (estimated 1–4 hours in rodents), which supports daily or twice-daily administration to maintain tissue-level concentrations. The compound exerts its primary effects during active tissue remodeling via continuous eNOS upregulation and VEGFR2 signaling.
TB-500 (Tβ4) binds G-actin in a 1:1 complex that acts as a tissue-level depot, extending its biological activity well beyond its plasma half-life. Published protocols consistently use 2–3× weekly dosing with equivalent or superior outcomes to daily administration in rodent models. Overdosing frequency with TB-500 does not improve outcomes and increases cost.
Phase-Matched Protocol Design
| Repair Phase | Duration | Primary Driver | BPC-157 Role | TB-500 Role |
|---|---|---|---|---|
| Inflammatory | Days 1–5 | Macrophage/neutrophil response | NO/eNOS anti-inflammatory support | NF-κB suppression, actin mobilization |
| Proliferative | Days 5–21 | Fibroblast/angiogenesis | VEGFR2 angiogenesis, FAK cell migration | ILK/Akt progenitor cell recruitment |
| Remodeling | Weeks 3–12 | Collagen crosslinking/maturation | Continued eNOS support, tendon remodeling | Reduced; maintenance doses may suffice |
Step 4: Injection Site Rotation
When running both compounds simultaneously, injection site rotation becomes important — particularly in small rodent subjects where abdominal SC sites are limited. Published rodent protocols typically use anterior and posterior SC abdominal quadrants in rotation.
- BPC-157 SC sites (rodent): Rotate anterior-left, anterior-right, posterior-left, posterior-right abdominal SC quadrants on a 4-site cycle
- TB-500 SC sites (rodent): Use dorsal/neck scruff SC sites for TB-500 (commonly used in Bock-Marquette protocols) to separate from BPC-157 injection zones
- Allow 48+ hours before re-using any individual injection site
- For IP administration of BPC-157: lower-left abdominal quadrant is standard; tilt animal head-down to move viscera
- Inspect injection sites at each administration for any nodule formation or inflammation indicating poor technique
Visit the Nexphoria Injection Site Diagram tool at /tools/injection-site-diagram for visual guides to both SC abdominal and SC dorsal injection techniques.
Step 5: Weekly Schedule Template (3-Month Protocol)
The following schedule is derived from published multi-compound rodent protocols and represents a practical integration of both compounds over a 12-week (3-month) research cycle.
| Day | BPC-157 (10 µg/kg SC) | TB-500 (500 µg/kg SC) | Notes |
|---|---|---|---|
| Monday | ✓ Inject | ✓ Inject | Week start — log weights, note observations |
| Tuesday | ✓ Inject | — | BPC-157 only |
| Wednesday | ✓ Inject | ✓ Inject | Midweek TB-500 dose |
| Thursday | ✓ Inject | — | BPC-157 only |
| Friday | ✓ Inject | ✓ Inject | End-of-week TB-500 dose |
| Saturday | ✓ Inject | — | BPC-157 only |
| Sunday | — | — | Rest day (optional BPC-157 if 7-day protocol) |
This yields approximately 6 BPC-157 doses/week and 3 TB-500 doses/week, consistent with published study designs. Adjust BPC-157 to 7-day daily if your research question involves GI mucosal models (where daily dosing has the most evidence).
Phase Adjustments
- Weeks 1–4 (loading/acute): Use full doses of both compounds — this covers the inflammatory and early proliferative phases
- Weeks 5–8 (active remodeling): Continue BPC-157 daily; optionally reduce TB-500 to 2× / week if acute inflammation has resolved
- Weeks 9–12 (late remodeling): Some protocols reduce BPC-157 to 5 days/week at the original dose; others maintain daily. TB-500 can continue at 2× / week
- Washout (post-cycle): Allow 4-week minimum washout (≥10× half-life) before any repeat cycle or crossover design
Step 6: Biomarkers to Track
Biomarker selection should be driven by your research endpoint, but several panels are broadly applicable across tissue-repair BPC-157 + TB-500 studies.
| Biomarker | What It Measures | Timing | BPC-157 Effect | TB-500 Effect |
|---|---|---|---|---|
| CBC (WBC, neutrophils, lymphocytes) | Immune/inflammatory status | Baseline, weeks 4, 8, 12 | Mild lymphocyte modulation | NF-κB — reduced neutrophil infiltrate |
| CMP (ALT, AST, BUN, creatinine) | Hepatic and renal safety | Baseline, weeks 6, 12 | Gastroprotective — may lower ALT in ulcer models | Generally neutral |
| IGF-1 | Growth factor signaling | Baseline, weeks 6, 12 | Mild indirect elevation via VEGF crosstalk | Modest elevation via ILK/PI3K axis |
| VEGF (serum or tissue) | Angiogenesis marker | Baseline, endpoint necropsy | Primary inducer via VEGFR2 | Secondary contributor via ILK/Akt |
| Collagen content (tissue assay) | Repair quality marker | Necropsy endpoint | Increases collagen organization | Increases collagen crosslinking |
| Inflammatory cytokines (IL-6, TNF-α) | Acute phase response | Baseline, weeks 2, 4, 8 | Reduces IL-6/TNF-α | Reduces NF-κB-driven cytokines |
Use the Nexphoria Biomarker Reference tool at /tools/biomarker-reference for normal ranges, optimal testing frequencies, and compound-specific effects across 32 biomarkers.
Step 7: Storage and Vial Management
- Lyophilized (unreconstituted) BPC-157 and TB-500: Store at −20°C, protected from light and moisture. Shelf life: 18–24 months lyophilized
- Reconstituted vials: Store at 2–8°C (refrigerator) in the dark. Use within 28 days of reconstitution
- Never freeze a reconstituted vial — ice crystal formation causes aggregation and peptide bond stress
- Label each reconstituted vial with: compound name, concentration (µg/mL), reconstitution date, expiry date (28 days post-reconstitution)
- Use the Nexphoria Vial Inventory Tracker at /tools/vial-inventory-tracker to track reconstitution dates, expiry, and remaining vials
Step 8: Research Design Considerations
- Include a vehicle control arm (BAC water only) in addition to individual compound arms and the combination arm — a full factorial 2×2 design (BPC-157±, TB-500±) with 4 groups is ideal for attribution
- Standardize injury timing relative to compound administration — most published protocols begin dosing on the day of injury induction (Day 0) or Day 1 post-injury
- Use the same reconstitution concentration across all groups — preparing BPC-157 at different concentrations across groups introduces injection volume as a confound
- Blind the study — have an assistant prepare and label syringes so the administering researcher is unaware of group assignment
- Include both sexes if possible — BPC-157 and TB-500 both show sex-linked differences in GI and cardiac models respectively
- Document injection sites and technique systematically — site-related variability is a common source of noise in rodent SC studies
Building Your Protocol
Once you understand the doses, timing, and design principles above, the fastest way to generate a complete printable protocol is through the Nexphoria Protocol Template Generator at /tools/protocol-template-generator. Select BPC-157 and TB-500, enter your doses and cycle length, and the tool generates a formatted study protocol with reconstitution notes, weekly schedule, biomarker tracking section, and a full RUO disclaimer.
For weekly injection scheduling in detail, use the Dosing Frequency Planner at /tools/dosing-frequency-planner to auto-distribute injections across days of the week with per-day dose totals. To track costs across cycle lengths, the Cost Per Dose Calculator at /tools/cost-per-dose-calculator outputs weekly, monthly, and vial-duration estimates for both compounds.